Fig. 4: Both ibrutinib-resistant and -naive TCL1-CLL respond to carfilzomib treatment. | Nature Communications

Fig. 4: Both ibrutinib-resistant and -naive TCL1-CLL respond to carfilzomib treatment.

From: Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL

Fig. 4: Both ibrutinib-resistant and -naive TCL1-CLL respond to carfilzomib treatment.The alt text for this image may have been generated using AI.

A Experimental outline of CFZ treatment in TCL1-AT mice. Created in BioRender. Zapatka, M. (2025) https://BioRender.com/a06v191. B C57BL/6 mice were injected with either ibrutinib-naïve (left panel) or -resistant (right panel) TCL1-CLL cells. Ibrutinib-naïve: ns = 0.0535; ∗p = 0.0227, ∗∗∗∗p < 0.0001. Ibrutinib-resistant: ns = 0.0586; ∗p = 0.0282, ∗∗∗∗p < 0.0001. Absolute number of CD19+ CD5+ TCL1-CLL cells in spleen (C) and in the inguinal lymph nodes (LN) (D). Spleen: ∗p = 0.0232; ∗∗∗p = 0.0005, ns = 0.9318, ∗∗∗p = 0.0003. LN: ns = 0.3279, ∗∗∗p = 0.0002, ∗∗∗∗p < 0.0001. Spleen (E) and liver (F) weights of mice 5 weeks after TCL1-CLL transplantation. n = 10 each group. Spleen weight: ∗p = 0.0155, ∗∗p = 0.0062, ∗∗∗p = 0.0010. Liver weight: ∗∗∗p = 0.0002, ns = 0.9772, ∗∗p = 0.0012. Mice treated with vehicle are represented by circular symbols, mice treated with CFZ are represented by squared symbols. Data are mean ± SD and were analyzed by two-tailed unpaired Student’s t test.

Back to article page